A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of S-297995 for the Treatment of Opioid-induced Constipation (OIC) in Cancer Patients

Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of S-297995 for the Treatment of Opioid-induced Constipation (OIC) in Cancer Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Naldemedine (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Sponsors Shionogi
  • Most Recent Events

    • 26 Apr 2017 Results published in the Journal of Clinical Oncology
    • 02 Jun 2015 Primary endpoint has been met (Chang in frequency of spontaneous bowel movements), according to an abstract presented at at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top